Contineum Therapeutics (CTNM)

The company’s pipeline includes PIPE-791, an antagonist of the lysophosphatidic acid 1, or LPA1, receptor. LPA1 signaling has been associated with fibrosis, pain, and inflammatory processes, making it a target of interest in diseases such as idiopathic pulmonary fibrosis and certain chronic pain conditions. By blocking this receptor, Contineum aims to interrupt pathways that may contribute to tissue scarring and abnormal pain signaling.

Contineum is also developing PIPE-307, a selective inhibitor of the M1 muscarinic receptor. The candidate is being evaluated in neurological and neuropsychiatric settings, including relapsing-remitting multiple sclerosis and depressive disorders. The scientific rationale includes the potential role of M1 receptor modulation in remyelination and central nervous system function, areas where new oral therapies could have meaningful clinical value.

As a listed biotechnology company, Contineum’s progress depends on clinical trial data, regulatory interactions, intellectual property protection, and access to capital. Its portfolio is differentiated by a focus on small molecules directed at challenging disease biology rather than symptomatic treatment alone. The company remains in the development stage, so its value is closely tied to whether its lead candidates can demonstrate safety, target engagement, and durable clinical benefit.